Free Newsletter
$200M vaccine plant for China; Researchers advance bowel cancer vaccine;
Vaccine Market
Canada's Microbix Biosystems is plotting a $200 million flu vaccine plant in Hunan province. The cooperative deal puts Microbix in partnership with the Hunan government, which will put up $100 million of the funding. The rest will come from Microbix's licensing partners. Report
Supply constraints for an ingredient in a shingles vaccine has forced Merck to warn about looming shipping delays for Zostavax. Article
Health officials in the U.S. are hoping that a new 5-in-1 vaccine will improve compliance on recommended vaccinations in the U.S. by reducing the complex number of vaccinations that are recommended. Story
Canada's Bioniche Life Sciences says it has secured the financing necessary to scale-up its vaccine production facility. Story
Vaccine Research
Insight into the unique immune system of intestines has helped advance an experimental bowel cancer vaccine, say researchers at the Kimmel Cancer Centre at Thomas Jefferson University. Article
DynPort Vaccine has won the federal contract to develop a new plague vaccine. Story
Medicago announced additional positive results for its H5N1 avian flu vaccine from a preclinical immunogenicity study performed in ferrets. Release
The Albany Medical College has won a $5.4 million grant to work on a new universal flu vaccine. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




